Drug Trial Radar · NCT06577025
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Aug 20, 2024
Primary completion
Sep 2, 2030
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.
Conditions
- Multiple Myeloma
Interventions
Cilta-celDrug
Cilta-cel infusion will be administered intravenously.
TalquetamabDrug
Talquetamab will be administered subcutaneously.
DaratumumabDrug
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
TeclistamabDrug
Teclistamab will be administered subcutaneously.
BortezomibDrug
Bortezomib will be administered subcutaneously as a part of induction.
LenalidomideDrug
Lenalidomide will be administered orally as a part of induction.
DexamethasoneDrug
Dexamethasone will be administered orally as a part of induction.
CyclophosphamideDrug
Cyclophosphamide will be administered intravenously as a part of conditioning regimen.
FludarabineDrug
Fludarabine will be administered intravenously as a part of conditioning regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Response with Curative PotentialTime frame: Up to 5 years
- Progression Free Survival (PFS) Rate at 3-YearTime frame: At 3-year
- PFS Rate at 5-YearTime frame: At 5-year
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of California San Francisco
San Francisco, California
University of Iowa Hospital and Clinics
Iowa City, Iowa
Memorial Sloan Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Peter MacCallum Cancer Centre
Melbourne, Australia
The Alfred Hospital
Melbourne, Australia
IDOR - Regional Bahia
Salvador, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
São Paulo, Brazil
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, Brazil
Universitaetsklinikum Heidelberg
Heidelberg, Germany
Universitaetsklinikum Tuebingen
Tübingen, Germany
Universitatsklinikum Wurzburg
Würzburg, Germany
Hosp. Univ. 12 de Octubre
Madrid, Spain
Hosp Clinico Univ de Salamanca
Salamanca, Spain
Hosp. Univ. Marques de Valdecilla
Santander, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.